ASPI at a glance
ASP Isotopes Inc. (ASPI, SEC CIK 1921865) filed its latest 10-K annual report on April 10, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on October 2, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ASP Isotopes Inc. (ASPI) reported revenue of $23.8 million (up 475.5% from FY2024) and a net loss of $159.8 million. Diluted EPS was -$2.11.
- As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding ASP Isotopes Inc. (ASPI) shares worth $143.3 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Ryan Robert John Andrew on September 30, 2026 of 15,000 shares at $2.68 per share.
- In the last 90 days, ASPI insiders reported 2 open-market purchases ($62K) and 6 open-market sales ($1.2M) on Form 4, a net sale of $1.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $23.8M
- +475.5% vs prior year
- Insiders · 90 days
- 2 buys · 6 sells
- Net −$1.2M
- 13F holders
- 22 funds
- $143.3M · +1 vs prior quarter
- Latest 8-K
- Sep 8, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New merger-completion risk triggered by June 25, 2026 agreement, including ENDRA stockholder approval and S-4 effectiveness
- Merger termination deadline of December 24, 2026 if closing conditions remain unsatisfied
- Regulatory risk from required U.S. International Development Finance Corporation consent under Tetra4’s finance agreement
- Operational risk from delayed integration, key-employee loss, and customer relationship disruption
- Financing risk from Noble’s approximately $50 million investment and ENDRA’s minimum $3.8 million cash condition
AI summary of the ASPI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Press release contains forward-looking statements subject to material risks and uncertainties
- Investors should rely on the company’s Form 10-K and SEC filings for risk factors
Item EX-99.1: Item EX-99.1
- Capital Markets Day signals transition from development to early commercialization across nuclear medicine, helium, LNG, electronics and nuclear fuels
- Revenue catalysts include Phase 1 liquid helium production, radiopharmacy growth and first commercial stable-isotope shipments over the next 12 months
Item 7.01: Regulation FD Disclosure
- Press release contains forward-looking statements subject to PSLRA safe-harbor protections
- Disclosure signals projections and expectations may differ materially from actual results
Item EX-99.1: Item EX-99.1
- Tetra4 entered commissioning of Phase 1 liquid helium plant, targeting first customer deliveries in September 2026
- Phase 1 capacity: 2,500 GJ/day LNG and 70 Mcf/day helium, with commercial production expected in Q3 2026
AI summaries of ASPI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ASPI
Don't miss the next ASPI filing
- Alerts as it files. A push when ASPI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ASPI, by share count.
- Ask anything. An AI agent that reads every ASPI filing and answers with sources.
ASPI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ryan Robert John Andrew | Buy | Sep 30, 2026 | 15,000 | $2.68 |
| Ryan Robert John Andrew | Buy | Sep 28, 2026 | 8,000 | $2.70 |
| Ainscow Robert | Sell | Sep 8, 2026 | 8,438 | $4.29 |
| Mann Paul Elliot | Sell | Sep 4, 2026 | 83,759 | $4.10 |
| Mann Paul Elliot | Sell | Sep 3, 2026 | 83,758 | $3.92 |
| Ainscow Robert | Sell | Sep 2, 2026 | 25,000 | $3.90 |
| Ainscow Donald George | Sell | Sep 2, 2026 | 23,678 | $3.89 |
| Mann Paul Elliot | Sell | Sep 2, 2026 | 83,758 | $3.91 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.1M | $23.8M |
| Gross Profit | - | $1.6M | $3.4M |
| Operating Income | - | -$26.4M | -$59.9M |
| Net Income | - | -$32.4M | -$159.8M |
| Gross Margin | - | 38.6% | 14.3% |
| Op. Margin | - | -635.9% | -251.2% |
| Net Margin | - | -782.4% | -670.2% |
| Balance Sheet | |||
| Total Assets | $27.5M | $94.3M | $498.0M |
| Equity | $16.3M | $47.9M | $204.2M |
| ROE | - | -67.7% | -78.3% |
| Per Share | |||
| EPS | - | $-0.63 | $-2.11 |
| Cash Flow | |||
| Operating CF | - | -$16.7M | -$37.8M |
| CapEx | - | $9.7M | $9.7M |
Source: XBRL data in ASP Isotopes Inc. (ASPI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ASPI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 22 | $143.3M |
| Q1 2026 | 21 | $95.6M |
| Q4 2025 | 21 | $135.6M |
| Q3 2025 | 22 | $188.4M |
| Q2 2025 | 22 | $85.6M |
| Q1 2025 | 17 | $29.7M |
| Q4 2024 | 13 | $25.5M |
| Q3 2024 | 6 | $4.0M |
- BlackRock+889.1K (+11%)
- Bank of America Corp+540.1K (+320%)
- State Street Corp+273.4K (+12%)
- Invesco Ltd+147.3K (+260%)
- Vanguard Portfolio Management LLC+138.2K (+14%)
- Morgan Stanley−414.1K (-26%)
- Citadel Advisors LLC−410.4K (-53%)
- Vanguard Capital Management LLC−77.5K (-2%)
- JPMorgan Chase & Co−32.4K (-12%)
- AQR Capital Management−10.2K (-43%)
- Allstate+23.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 144 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ASPI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 2, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| 10-Q | Aug 14, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 8-K | Jul 21, 2026 | - | Analysis | - |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | - | - |
Related Health Care companies
- FTK · FLOTEK INDUSTRIES INC/CN/Miscellaneous Chemical Products
- OEC · Orion S.A.Miscellaneous Chemical Products
- WDFC · WD 40 COMiscellaneous Chemical Products
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
ASPI SEC filings: frequently asked questions
Are ASPI insiders buying or selling?
In the last 90 days, ASP Isotopes Inc. (ASPI) officers, directors and 10% owners reported 2 open-market purchases worth $61,800 by 1 insider and 6 open-market sales worth $1.2 million by 3 insiders on Form 4, a net sale of $1.2 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ASPI stock?
As of June 30, 2026, the largest ASP Isotopes Inc. (ASPI) holders among the 13F filers tracked by SignalX were BlackRock ($57.3 million), Vanguard Capital Management LLC ($31.0 million), State Street Corp ($16.1 million), Morgan Stanley ($7.2 million), Vanguard Portfolio Management LLC ($6.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ASPI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ASP Isotopes Inc. (ASPI) reported revenue of $23.8 million (up 475.5% from FY2024) and a net loss of $159.8 million. Diluted EPS was -$2.11. The figures come from the XBRL data in the 10-K.
What did ASPI report in its latest 8-K?
ASP Isotopes Inc. (ASPI) filed an 8-K on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure). Press release contains forward-looking statements subject to material risks and uncertainties.
What are the latest ASPI SEC filings?
ASP Isotopes Inc. (ASPI) filed its latest 10-K annual report on April 10, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on October 2, 2026 and a Form 4 insider filing on October 1, 2026.
What is ASPI's SEC CIK number?
ASP Isotopes Inc. (ASPI)'s SEC Central Index Key (CIK) is 1921865. EDGAR lists every ASPI filing under that number.
Ask anything about ASPI
The research agent reads ASPI's filings, financials, insider trades and 13F holders, then answers with sources.